Angioplasty

Merit Medical Launches the basixALPHA™ Inflation Device

Retrieved on: 
Monday, November 28, 2022
Endoscopy, Heart, MMSI, Hospital, Physician, Radiology, PCI, Critical care, Merit, Angioplasty, Percutaneous coronary intervention, Exertion, Feedback, Artery, Cardiology, Medical imaging

SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA Inflation Device.

Key Points: 
  • SOUTH JORDAN, Utah, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the basixALPHA Inflation Device.
  • The basixALPHA is the latest addition to the Merit inflation device portfolio.
  • More than 1.2 million coronary angioplasty procedures are performed each year within the US.1
    As a leader in inflation device technology, Merit understands that inflation devices serve as staples in the cath lab, said Fred P. Lampropoulos, Merit Medicals Chairman and CEO.
  • ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Dalia Dawoud, MD, Named Co-Chair of the American Society of Diagnostic and Interventional Nephrology's 19th Annual Scientific Meeting

Retrieved on: 
Tuesday, November 15, 2022
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Hospitals, Clinical Trials, Other Health, Well, Small Satellite Research Laboratory, Hospital, NNA, Diagnosis, University of California, Riverside, Thrombectomy, MSO, ASC, Knowledge, TDAT, Dialysis, University, Angioplasty, Master of Science, Kidney, Health care, Medicine, Chronic kidney disease, Intervention, Research, Renal replacement therapy, Society, Physician, Maintenance, Polish Society of Nephrology, Nursing, Inland Empire, Practitioner, CKD, Kidney disease, Mentorship, Patient, Health, Nephrology, MD

She is the medical director of NAMGs Vascular Access Center and Ultrasound Laboratory as well as its ASC JV Manager.

Key Points: 
  • She is the medical director of NAMGs Vascular Access Center and Ultrasound Laboratory as well as its ASC JV Manager.
  • A native of Egypt, Dr. Dawoud especially credits her late father with inspiring her chosen specialty, nephrology.
  • When she was 16, her father was diagnosed with chronic kidney disease enduring many years of dialysis, and eventually, underwent a kidney transplant.
  • The American Society of Diagnostic and Interventional Nephrologys mission is to promote excellence in dialysis access care to improve outcomes for patients with kidney disease.

Coronary Stent Co-Inventor and Gene Therapy Pioneer, Dr. Richard Schatz, Joins GATC Health as Chairman of its Medical Advisory Board

Retrieved on: 
Thursday, November 10, 2022
National Academy of Inventors, Alumnus, American College of Cardiology, Duke University Hospital, Coronary circulation, Duke University, Health, Invention, Intelligence, Brooke Army Medical Center, Coronary artery disease, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, MAT, Biology, Risk, Angioplasty, National academy, Technology, State university system, Population, Lung, Drug discovery, Artificial intelligence, Multimedia, Disease, Degenerative disease, Mortality, GATC, Efficiency, Duke University School of Medicine, Nobel Prize, Precision medicine, Medicine, Buffalo, Company, Science, Biological engineering, Moyamoya disease, University, Patient, Heart, Therapy, Stent, University of Texas Health Science Center at San Antonio, MD, FDA, Restenosis, American College, Medical device, Pharmaceutical industry, Cardiology

Dr. Schatz, a recognized international expert in interventional cardiology and co-inventor of the coronary stent, will propel GATC Health's development of novel therapeutics, diagnostics and genomic risk reports related to heart disease.

Key Points: 
  • Dr. Schatz, a recognized international expert in interventional cardiology and co-inventor of the coronary stent, will propel GATC Health's development of novel therapeutics, diagnostics and genomic risk reports related to heart disease.
  • "Dr Schatz leading our Medical Advisory Board as Chairman is a major endorsement of the value of our platform and its potential to support heart health," said Jeff Moses, President of GATC Health.
  • He was honored with both the distinguished alumnus award and the Lifetime Scholar Award by Duke University Medical Center.
  • GATC envisions the future of medicine now, where health is protected, disease is reversed and every person's unique biology is treated with precision.

$32.2 Billion Global Interventional Cardiology Devices Market Report to 2027: Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Medical Devices, Health, CAD, Diabetes, OCT, Plaque, Degenerative disease, TMR, Prevalence, Growth, Arrhythmia, Catheter, Hemostasis, Angioplasty, Atherectomy, Stent, COVID-19, CABG, Coronary artery disease, FFR, MI, IVUS, Hypertension, Solution, Pharmaceutical industry, Medical imaging

Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.

Key Points: 
  • Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.
  • Some of the commonly used devices include angioplasty balloons, stents, mitral, pulmonary and tricuspid valves, catheters, plaque modification and hemodynamic flow alteration devices.
  • Interventional cardiology and embolic protection devices are widely used to capture embolic debris to ensure continuous blood flow and preventing blockages.
  • The publisher provides an analysis of the key trends in each sub-segment of the global interventional cardiology devices market, along with forecasts at the global, regional and country level from 2022-2027.

FDA Clears Angioplasty Platform to Crack, Break, and Dilate Stenosis in Calcified Cardiovascular Disease and Hemodialysis Fistula

Retrieved on: 
Thursday, October 27, 2022
PTA, Gaps, Cardiovascular disease, Platform, XO, 2F, Patient, Sale, CLI, Stock, Dialysis, Amputation, Angioplasty, FDA, Fistula, Tri-City Medical Center, MD, OTW, SALT, Advanced cardiac life support, Multimedia, Popliteal, FACC, BTK, PAD, RX, Pharmaceutical industry, Medical device

SALT LAKE CITY, Oct. 27, 2022 /PRNewswire/ -- Transit Scientific, a pioneer in developing medical devices to treat calcified cardiovascular disease, dilate stenosed intimal hyperplasia, and access, cross, & deliver to distal vessels, announced today the XO RX 2.2F and XO RX 3.8F Platform received FDA clearance to crack, break, and dilate stenoses in peripheral arteries and arteriovenous dialysis fistula associated lesions.

Key Points: 
  • "The new 3.8F XO RX has a low profile and accommodates 20 cm balloons making it a good option for PAD and CLI disease.
  • The lower profile 2F version helps address gaps in treatment options currently available for BTK, tibiopedal, and pedal loop stenoses."
  • XO RX and XO OTW (over-the-wire) exoskeleton devices include up to (22) rotating struts that slide onto a broad range of off-the-shelf angioplasty balloons.
  • "Patients and clinicians need more tools to crack, break, and dilate occlusive lesions in patients with cardiovascular disease.

Global Pediatric Interventional Cardiology Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, Cardiology, VSD, COVID-19, Stenosis, Risk, Angioplasty, Atrial septal defect, PDA, Industry, Infection, Patient, Stent, Investment, Patent ductus arteriosus, Catheter, Cardiology, Atherectomy, Ventricular septal defect, Research, R, Hospital, ASD, Awareness, Non-governmental organization, Medical imaging, Potash

As compared to conventional cardiological treatments, pediatric interventional cardiology is more minimally invasive, thus reducing post-surgery complications.

Key Points: 
  • As compared to conventional cardiological treatments, pediatric interventional cardiology is more minimally invasive, thus reducing post-surgery complications.
  • How has the global pediatric interventional cardiology market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pediatric interventional cardiology market?
  • What is the structure of the global pediatric interventional cardiology market and who are the key players?

Sheridan N. Meyers, MD, FACC, is being recognized by Continental Who's Who as a Top Pinnacle Achiever for his exemplary career in the Medical field and in acknowledgment of his work in Academia

Retrieved on: 
Monday, September 26, 2022
Lyceum-Northwestern University, American Board of Internal Medicine, United States Department of Veterans Affairs, American College, American Board of Commissioners for Foreign Missions, Feinberg School of Medicine, MD, Angioplasty, Hospital, Medical degree, Catheter, Echocardiography, Army of the United States, McGaw Medical Center, Internal medicine, Interventional cardiology, Order of United Commercial Travelers of America, ABIM, Commercial, Cardiovascular disease, Birth, Heart, Medicine, Multimedia, MASH, American College of Cardiology, Education, Emeritus, Mentorship, View, John H. Stroger Jr. Hospital of Cook County, Science, Cardiology, Northwestern Memorial Hospital, Chemistry, Biology

During his practice, Dr. Meyers worked primarily in the cardiac catheterization lab, specializing in angioplasty and echocardiography to determine the appropriate diagnoses of various heart disorders.

Key Points: 
  • During his practice, Dr. Meyers worked primarily in the cardiac catheterization lab, specializing in angioplasty and echocardiography to determine the appropriate diagnoses of various heart disorders.
  • Cardiology is a branch of medicine that deals with the diseases of the heart and some parts of the circulatory system.
  • In pursuit of his medical career, Dr. Meyer obtained a Bachelor of Science in Biology and Chemistry from Northwestern University.
  • He earned his Medical Degree from Northwestern Medical School in 1961.

SUPIRA MEDICAL ANNOUNCES SUCCESSFUL FIRST-IN-HUMAN USE OF ITS NEXT GENERATION PERCUTANEOUS VENTRICULAR ASSIST DEVICE

Retrieved on: 
Friday, September 16, 2022
Safety, Trial of the century, LOS, Risk, Angioplasty, Percutaneous, Coronary artery disease, DRS, Patient, University of California, Davis, Physician, University Medical Center, Disease, CEO, Solution, CS, Cardiogenic shock, Hemodynamics, Heart, Interventional cardiology, University, Structural heart disease, Medical device, Medicine

LOS GATOS, Calif., Sept. 16, 2022 /PRNewswire/ -- Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).

Key Points: 
  • The prospective, single-arm, single-center study will evaluate the safety and performance of Supira's low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).
  • "Today marks an important milestone as Supira transitions to a clinical-stage company," commented Dr. Nitin Salunke, President and CEO of Supira Medical.
  • Percutaneous ventricular assist devices are used during stent placement or angioplasty to provide mechanical support for high-risk patients with severe coronary artery disease or comorbidities.
  • Supira Medical, a privately held portfolio company of Shifamed, is focused on development of a next generation percutaneous ventricular assist device for use in high-risk patients undergoing interventional procedures.

LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement

Retrieved on: 
Tuesday, August 23, 2022
Medical Devices, Health, Diabetes, Health Technology, General Health, Cardiology, Mortality, Chronic pain, Artery, University, Degenerative disease, Obesity, Chronic limb threatening ischemia, Government, University of Michigan School of Information, Amputation, Ageing, Disease, Angioplasty, Sale, Public health, Leg, Policy, PAD, Economics, Vein, Kidney disease, Quality of life, Infection, Health policy, Harvard University, Patient, Prevalence, Wound healing, Population, Peripheral artery disease, Perfusion, Avalere Health, University of Michigan School of Public Health, Diabetes, Face, Coronary artery disease, Foot, CE marking, Pharmaceutical industry, Medical imaging, Medtronic

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement.

Key Points: 
  • LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement.
  • Prior to joining LimFlow, she worked with Medtronic for more than seven years, most recently as the global lead for reimbursement and health economics for the coronary and renal denervation division.
  • Prior to Medtronic, she served as a healthcare policy and reimbursement consultant at Avalere Health, a premier Washington, DC-based firm.
  • in government, economics and health policy from Harvard University, and holds an executive masters degree in health management and policy from the University of Michigan School of Public Health.